登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07540390,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).
入选标准第 3 条
Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system).
入选标准第 5 条
Participation in another clinical trial of an investigational drug within 3 months prior to treatment.
排除标准第 4 条
Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L.
入选标准第 7 条
Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN.
入选标准第 8 条
Renal function: serum creatinine <1.5×ULN.
入选标准第 9 条
HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.
排除标准第 10 条
Age 18-65 years, male or non-pregnant female.
入选标准第 2 条
Positive pregnancy test in women of childbearing potential, or lactating women.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07540390,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation and signed informed consent. Age 18-65 years, male or non-pregnant female. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III). Previously untreated patients with no history of other malignancies; initial treatment for nasopharyngeal carcinoma. Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system). ECOG performance status 0-1, with no severe dysfunction of vital organs (heart, lung, liver, kidney, etc.). Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L. Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN. Renal function: serum creatinine <1.5×ULN.排除标准:Exclusion Criteria:
Patients with recurrent or distant metastatic nasopharyngeal carcinoma. Pathologically confirmed keratinizing squamous cell carcinoma (WHO type I). Receipt of systemic or topical glucocorticoid therapy within 4 weeks prior to enrollment. Participation in another clinical trial of an investigational drug within 3 months prior to treatment. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Patients with idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), radiation pneumonitis that is clinically symptomatic or requires steroid therapy, active pneumonitis, or other moderate-to-severe pulmonary diseases that significantly affect lung function. Comorbidities requiring long-term immunosuppressive medication or systemic/topical corticosteroids at immunosuppressive doses. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways) with documented disease progression at the time of study entry. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for medical management of asthma are excluded. HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA. Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine) within 4 weeks prior to enrollment. Positive pregnancy test in women of childbearing potential, or lactating women. Inability to comply with scheduled follow-up due to psychological, social, family, or geographical reasons.
引自 ClinicalTrials.gov, NCT07540390, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07540390,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。